Lista de obras -

210. NEURAPRO: A Multi-center RCT of Omega-3 Polyunsaturated Fatty Acids Versus Placebo in Young People at Ultra-High Risk of Psychotic Disorders: Medium-Term Outcome.

artículo científico publicado en 2017

22. The Effects of Antidepressant use on Clinical Outcomes in the NEURAPRO-E Trial.

artículo científico publicado en 2017

Clinical trajectories in the ultra-high risk for psychosis population

artículo científico publicado en 2018

Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

artículo científico publicado en 2020

Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

artículo científico publicado en 2019

Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

artículo científico publicado en 2020

Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.

artículo científico publicado en 2016

F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS.

artículo científico publicado en 2018

NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.

artículo científico publicado en 2015

Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

artículo científico publicado en 2018

O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL.

artículo científico publicado en 2018

Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis

artículo científico publicado en 2020

Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population

scientific article published on 17 June 2020

Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial.

artículo científico publicado en 2019

S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING.

artículo científico publicado en 2018

Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

scientific article published on 09 October 2019

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION.

artículo científico publicado en 2018

T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY.

artículo científico publicado en 2018

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

artículo científico publicado en 2019

The Public Health Impact and Policy Implications of Online Support Group Use for Mental Health in Singapore: Cross-Sectional Survey

artículo científico publicado en 2020

Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial

scientific article published on 21 November 2019

Lista de obras de

210. NEURAPRO: A Multi-center RCT of Omega-3 Polyunsaturated Fatty Acids Versus Placebo in Young People at Ultra-High Risk of Psychotic Disorders: Medium-Term Outcome.

22. The Effects of Antidepressant use on Clinical Outcomes in the NEURAPRO-E Trial.

Clinical trajectories in the ultra-high risk for psychosis population

Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.

F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS.

NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.

Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL.

Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis

Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population

Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial.

S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING.

Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION.

T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY.

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

The Public Health Impact and Policy Implications of Online Support Group Use for Mental Health in Singapore: Cross-Sectional Survey

Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial